Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 11
---
 to Clearmind Medicine Inc.

Our principal executive offices are located at
101 – 1220 W. 6th Ave, Vancouver, BC V6H1A5. Our telephone number is 973.536.1016. Our website address is https://www.clearmindmedicine.com/.
The information contained on our website and available through our website is not incorporated by reference into and should not be considered
a part of this prospectus, and the reference to our website in this prospectus is an inactive textual reference only.

<div align='center'>2</div>

January 2024 Offering

On January 11, 2024, we sold to several institutional investor an aggregate
of 1,468,000 common shares in a registered direct offering at a purchase price of $1.60 per share, and pre-funded warrants to purchase
up to 32,000 common shares at a purchase price of $1.5999, resulting in gross proceeds of approximately $2.4 million. In addition,
we issued to the investors unregistered common warrants, or the January 2024 PIPE Warrants, to purchase up to an aggregate of 1,500,000
common shares in the concurrent January 2024 Private Placement. The January 2024 PIPE Warrants are exercisable upon issuance at an exercise
price of $1.60 per common share, subject to adjustment as set forth therein, and have a 5-year term from the issuance date. The January
2024 PIPE Warrants may be exercised on a cashless basis if at the time of exercise thereof, there is no effective registration statement
registering the common shares underlying the January 2024 PIPE Warrants. We paid the placement agent in the registered direct offering
and January 2024 Private Placement a cash placement fee equal to 8.0% of the gross proceeds received in the registered direct offering
and $75,000 for reasonable legal fees and disbursements for the placement agent’s counsel.

In connection with the January 2024 Private Placement, the selling
shareholders named in this prospectus may offer and sell up to an aggregate of 1,126,480 common shares issuable upon exercise of the January
2024 PIPE Warrants.

Implications of Being an “Emerging Growth Company” and a Foreign Private Issuer

Emerging Growth Company

We are an “emerging growth company,”
as defined in Section 2(a) of the Securities Act of 1933, as amended, or